These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 31227936)

  • 61. Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
    Yao L; Mustafa N; Tan EC; Poulsen A; Singh P; Duong-Thi MD; Lee JXT; Ramanujulu PM; Chng WJ; Yen JJY; Ohlson S; Dymock BW
    J Med Chem; 2017 Oct; 60(20):8336-8357. PubMed ID: 28953386
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.
    Bhagwat N; Koppikar P; Keller M; Marubayashi S; Shank K; Rampal R; Qi J; Kleppe M; Patel HJ; Shah SK; Taldone T; Bradner JE; Chiosis G; Levine RL
    Blood; 2014 Mar; 123(13):2075-83. PubMed ID: 24470592
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
    Amaru Calzada A; Todoerti K; Donadoni L; Pellicioli A; Tuana G; Gatta R; Neri A; Finazzi G; Mantovani R; Rambaldi A; Introna M; Lombardi L; Golay J;
    Exp Hematol; 2012 Aug; 40(8):634-45.e10. PubMed ID: 22579713
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
    Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
    J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
    [TBL] [Abstract][Full Text] [Related]  

  • 65. JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.
    Irino T; Uemura M; Yamane H; Umemura S; Utsumi T; Kakazu N; Shirakawa T; Ito M; Suzuki T; Kinoshita K
    PLoS One; 2011; 6(7):e22148. PubMed ID: 21789226
    [TBL] [Abstract][Full Text] [Related]  

  • 66. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
    Fleischman AG; Aichberger KJ; Luty SB; Bumm TG; Petersen CL; Doratotaj S; Vasudevan KB; LaTocha DH; Yang F; Press RD; Loriaux MM; Pahl HL; Silver RT; Agarwal A; O'Hare T; Druker BJ; Bagby GC; Deininger MW
    Blood; 2011 Dec; 118(24):6392-8. PubMed ID: 21860020
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).
    Yao L; Ramanujulu PM; Poulsen A; Ohlson S; Dymock BW
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2636-2640. PubMed ID: 29945795
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
    Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
    Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reversine exhibits antineoplastic activity in JAK2
    Lima K; Carlos JAEG; Alves-Paiva RM; Vicari HP; Souza Santos FP; Hamerschlak N; Costa-Lotufo LV; Traina F; Machado-Neto JA
    Sci Rep; 2019 Jul; 9(1):9895. PubMed ID: 31289316
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Role of additional novel therapies in myeloproliferative neoplasms.
    Fiskus W; Ganguly S; Kambhampati S; Bhalla KN
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):959-80. PubMed ID: 23009932
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.
    Gorantla SP; Mueller TA; Albers-Leischner C; Rudelius M; von Bubnoff N; Duyster J
    Mol Oncol; 2024 Feb; 18(2):415-430. PubMed ID: 38104968
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
    Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeting glutamine metabolism in myeloproliferative neoplasms.
    Zhan H; Ciano K; Dong K; Zucker S
    Blood Cells Mol Dis; 2015 Oct; 55(3):241-7. PubMed ID: 26227854
    [TBL] [Abstract][Full Text] [Related]  

  • 74. New generation small-molecule inhibitors in myeloproliferative neoplasms.
    Passamonti F; Maffioli M; Caramazza D
    Curr Opin Hematol; 2012 Mar; 19(2):117-23. PubMed ID: 22227528
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.
    Greenfield G; McPherson S; Mills K; McMullin MF
    J Transl Med; 2018 Dec; 16(1):360. PubMed ID: 30558676
    [TBL] [Abstract][Full Text] [Related]  

  • 76. HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.
    Yue L; Sharma V; Horvat NP; Akuffo AA; Beatty MS; Murdun C; Colin C; Billington JMR; Goodheart WE; Sahakian E; Zhang L; Powers JJ; Amin NE; Lambert-Showers QT; Darville LN; Pinilla-Ibarz J; Reuther GW; Wright KL; Conti C; Lee JY; Zheng X; Ng PY; Martin MW; Marshall CG; Koomen JM; Levine RL; Verma A; Grimes HL; Sotomayor EM; Shao Z; Epling-Burnette PK
    Blood; 2020 Jan; 135(3):191-207. PubMed ID: 31750881
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Circulating CD133+/–CD34– Have Increased c-
    Uslu Bıçak İ; Tokcan B; Yavuz AS; Tokdemir SS
    Turk J Haematol; 2023 Feb; 40(1):28-36. PubMed ID: 36458557
    [TBL] [Abstract][Full Text] [Related]  

  • 78. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
    Saenz DT; Fiskus W; Manshouri T; Rajapakshe K; Krieger S; Sun B; Mill CP; DiNardo C; Pemmaraju N; Kadia T; Parmar S; Sharma S; Coarfa C; Qiu P; Verstovsek S; Bhalla KN
    Leukemia; 2017 Mar; 31(3):678-687. PubMed ID: 27677740
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.
    Nitulescu II; Meyer SC; Wen QJ; Crispino JD; Lemieux ME; Levine RL; Pelish HE; Shair MD
    EBioMedicine; 2017 Dec; 26():112-125. PubMed ID: 29239838
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
    Rosenthal A; Mesa RA
    Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.